FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

TD Bank has committed $100,000 to support the MUSC Hollings Cancer Center’s SC AMEN program, a community outreach initiative that brings education, screenings, and health services assistance to Black men 40 to 69 years old in South Carolina.

November 22, 2024

Vol.50 No.44

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Researchers at City of Hope found that taking white button mushroom pills reduces a class of immune cells called myeloid-derived suppressor cells, which has been linked to cancer development and spread.

November 22, 2024

Vol.50 No.44

Clinical Roundup

UVA Health tests focused ultrasound to increase immune response in melanoma

A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation

FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

November 22, 2024

Vol.50 No.44

FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

YOU MAY BE INTERESTED IN

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

UVA Health tests focused ultrasound to increase immune response in melanoma

FDA approves new alternative standard related to mammography report assessments

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation

Renew today!

Subscriber content

Never miss an issue!

Login